Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
SK Biopharmaceuticals developed cenobamate, an anti-seizure medication independently discovered, clinically validated, FDA approved, and commercialized in the U.S. It also discovered solriamfetol for sleep disorders. The company is expanding into oncology with new modalities such as targeted protein degraders, radiopharmaceutical therapies, cell & gene therapies. Cenobamate continues to expand globally with ongoing Phase 3 trials in Asia.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on SK Medical.